4D Molecular Therapeutics Inc (FDMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 3,781 | 3,047 | 85,090 | 90 | 15 |
| Gross Profit | 3,781 | 3,047 | 85,090 | 90 | 15 |
| Operating Expenses | 80,806 | 76,667 | 70,375 | 61,275 | 59,471 |
| Operating Income | -77,025 | -73,620 | 14,715 | -61,185 | -59,456 |
| Other Income | 4,089 | 4,860 | 4,682 | 4,309 | 4,798 |
| Pre-tax Income | -72,936 | -68,760 | 19,397 | -56,876 | -54,658 |
| Net Income Continuous | -72,936 | -68,760 | 19,397 | -56,876 | -54,658 |
| Net Income | $-72,936 | $-68,760 | $19,397 | $-56,876 | $-54,658 |
| EPS Basic Total Ops | -1.04 | -1.01 | 0.43 | -1.01 | -0.98 |
| EPS Basic Continuous Ops | -1.04 | -1.01 | 0.43 | -1.01 | -0.98 |
| EPS Diluted Total Ops | -1.04 | -1.01 | 0.43 | -1.01 | -0.98 |
| EPS Diluted Continuous Ops | -1.04 | -1.01 | 0.43 | -1.01 | -0.98 |
| EPS Diluted Before Non-Recurring Items | -1.04 | -1.01 | 0.43 | -1.01 | -0.98 |
| EBITDA(a) | $-76,735 | $-73,485 | $14,784 | $-61,078 | $-59,456 |